PDS Biotechnology Corp
PDSB
查看详细走势图
0.890USD
+0.014+1.57%
收盘 12/19, 16:00（美东）报价延迟15分钟
42.46M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.57%
5天
-8.62%
1月
+17.72%
6月
-45.06%
今年开始到现在
-45.39%
1年
-46.05%
查看详细走势图
TradingKey PDS Biotechnology Corp股票评分
单位: USD 更新时间: 2025-12-19操作建议
PDS Biotechnology Corp当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名153/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.50。中期看，股价处于下降通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
PDS Biotechnology Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
7.500
目标均价
+734.91%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
PDS Biotechnology Corp亮点
亮点风险
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
PDS Biotechnology Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
PDS Biotechnology Corp简介
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
公司代码PDSB
公司PDS Biotechnology Corp
CEOBedu-Addo (Frank)
网址https://www.pdsbiotech.com
常见问题
PDS Biotechnology Corp(PDSB)的当前股价是多少？
PDS Biotechnology Corp(PDSB)的当前股价是 0.890。
PDS Biotechnology Corp的股票代码是什么？
PDS Biotechnology Corp的股票代码是PDSB。
PDS Biotechnology Corp股票的52周最高点是多少？
PDS Biotechnology Corp股票的52周最高点是2.200。
PDS Biotechnology Corp股票的52周最低点是多少？
PDS Biotechnology Corp股票的52周最低点是0.703。
PDS Biotechnology Corp的市值是多少？
PDS Biotechnology Corp的市值是42.46M。
PDS Biotechnology Corp的净利润是多少？
PDS Biotechnology Corp的净利润为-37.61M。
现在PDS Biotechnology Corp(PDSB)的股票是买入、持有还是卖出？
根据分析师评级，PDS Biotechnology Corp(PDSB)的总体评级为买入，目标价格为7.500。
PDS Biotechnology Corp(PDSB)股票的每股收益（EPS TTM）是多少
PDS Biotechnology Corp(PDSB)股票的每股收益（EPS TTM）是-0.814。
相关品种
